In the last trading session, 2.74 million Adma Biologics Inc (NASDAQ:ADMA) shares changed hands as the company’s beta touched 0.58. With the company’s per share price at $18.71 changed hands at $0.04 or 0.21% during last session, the market valuation stood at $4.42B. ADMA’s last price was a discount, traded about -26.35% off its 52-week high of $23.64. The share price had its 52-week low at $5.88, which suggests the last value was 68.57% up since then. When we look at Adma Biologics Inc’s average trading volume, we note the 10-day average is 3.18 million shares, with the 3-month average coming to 2.54 million.
Analysts gave the Adma Biologics Inc (ADMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended ADMA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Adma Biologics Inc’s EPS for the current quarter is expected to be 0.14.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA was in green as seen at the end of in last trading. With action 7.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 9.10%, with the 5-day performance at 7.84% in the green. However, in the 30-day time frame, Adma Biologics Inc (NASDAQ:ADMA) is 17.67% up. Looking at the short shares, we see there were 14.23 million shares sold at short interest cover period of 6.64 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need a downside of -3.94% from its current market value. According to analyst projections, ADMA’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a 3.79% surge from its current level, while the stock would need to tank 3.79% for it to hit the projected low.
Adma Biologics Inc (ADMA) estimates and forecasts
Year-over-year growth is forecast to reach 15.59% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 115.5M. 2 analysts are of the opinion that Adma Biologics Inc’s revenue for the current quarter will be 120.7M. The company’s revenue for the corresponding quarters a year ago was 81.88M and 107.19M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 41.07%. The estimates for the next quarter sales put growth at 12.60%.
The 2025 estimates are for Adma Biologics Inc earnings to increase by 43.56%, but the outlook for the next 5-year period is at 31.08% per year.
ADMA Dividends
Adma Biologics Inc is expected to release its next quarterly earnings report on 2025-Mar-02.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.65% of Adma Biologics Inc shares while 88.67% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 91.09%. There are 88.67% institutions holding the Adma Biologics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 8.1462% of the shares, roughly 18.64 million ADMA shares worth $208.45 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . With 15.2 shares estimated at $284.3 million under it, the former controlled 6.43% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.96% of the shares, roughly 7.0 shares worth around $131.0 million.
